Close mobile menu×
Close mobile menu

Gerald B. Appel, MD

Board Certifications: 
Nephrology, Internal Medicine
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-3273

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

America's Top Doctor
NY Top Doctor

Board Certifications

  • Nephrology
  • Internal Medicine

Clinical Expertise

  • Lupus
  • Glomerulonephritis
  • Nephrotic Syndrome

Education & Training

  • Albert Einstein College of Medicine - Yeshiva University
  • Internship: Columbia Presbyterian Medical Center, NY
  • Residency: Columbia Presbyterian Medical Center, NY
  • Fellowship: Columbia Presbyterian Medical Center, NY
  • Fellowship: Yale-New Haven Hospital

Honors & Awards

  • College: Graduated in three years "with Distinction in all subjects". Phi Beta Kappa. Medical School: Alpha Omega Alpha (Junior Year), Upjohn Achievement Award for Excellence in Clinical Skills.
  • 1988 Distinguished Teacher Award of the College of Physicians & Surgeons
  • 1989 Albert Douglas Award of Medical Society of New York State for excellence in clinical teaching
  • 1992-2014 Listed in "Best Doctors in New York" New York Magazine
  • 1994-2104 Listed in "Best Doctors in American" Text
  • 1994-2013 Listed in "How to Find the Best Doctors in the N.Y. Metro Area", Castle Connoly Guide

About Gerald Appel

Gerald B. Appel, MD, is Co-Director of Clinical Nephrology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York, New York, and is a tenured Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons. He is Director of the Glomerular Kidney Disease Center at Columbia. He received his undergraduate BA from Cornell University graduating in three years with distinction in all subjects and as a member of phi beta kappa. He

received his medical degree from Albert Einstein College of Medicine, NY in 1972 where he was elected to the medical honor society Alpha Omega Alpha. He completed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center, then completed fellowships in nephrology at both Columbia-Presbyterian Med. Ctr.(1975-1976) and at Yale-New Haven Medical Center, New Haven, Connecticut (1976-1978).

Dr. Appel has served as an officer and President of The NY Society of Nephrology, he has served on the Medical Advisory Board and as the Chairman of the Research Committee of the National Kidney Foundation ( NKF ) of NY-NJ and The Kidney and Urology Foundation of America, and as Chair of the Council of Glomerulonephritis of the NKF of the United States.

Dr Appel has been listed in New York Magazine as one of the “Best Doctors in New York” annually between 1992 and 2013, and is listed in “Best Doctors in America,” He has served on the editorial board of a number of journals including roles as an Associate Editor of Clinical JASN and he is currently on the editorial board of Up-To-Date. He has been the director of a number of educational courses including The Columbia U Internal Medicine Course in NYC , Renal Biopsy in Medical Diseases of the Kidney in NYC, and for many years had directed the annual course in The Treatment of Glomerular Diseases at the American Society of Nephrology meetings ( 1998-20010 ). Dr Appel has authored and co-authored over 300 peer-reviewed articles and book chapters. He has received numerous awards including the Albert Douglas Award of the Medical Society of NY State for excellence in clinical teaching, The Lester Honig Award of the NY-NJ Kidney Foundation, the Distinguished Service Award of the Nephcure Foundation, and twice the Teacher of the Year Award by Columbia University's medical school classes. In 2012 he delivered the Dornfeld Lecture at George Washington U. and the Chandos Lecture at the UK Society of Nephrology He was awarded The Donald Seldin Award by the National Kidney Foundation of the US at their annual meeting in 2012. His career has been devoted to the care and welfare of patients with diseases of the kidney.

Academic Titles

  • Professor of Medicine at CUMC

Administrative Positions

  • Co-Director, Clinical Nephrology

Committee/Societies/Council Memberships

  • American Society of Nephrology
  • International Society of Nephrology
  • New York Society of Nephrology
  • Fellow of American College of Physicians
  • Fellow of The American Society of Nephrology

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Medicare

  • Traditional Medicare (NY)

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

TRICARE

  • TRICARE

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO
  • The Empire Plan (NYSHIP)

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
Room 202
New York, New York 10032
Phone:
(212) 305-3273
Fax:
(212) 342-1814
Primary

Research

Grants

NATURAL HISTORY OF C3 GLOMERULOPATHY (P&S Industry Clinical Trial)

Mar 22 2019 - Mar 22 2024

A PHASE 2 TRIAL OF THE SAFETY AND EFFICACY OF BARDOXOLONE METHYL IN PATIENTS WITH RARE CHRONIC KIDNEY DISEASES (P&S Industry Clinical Trial)

Apr 27 2018 - Apr 27 2023

A PHASE 2, PROOF-OF-CONCEPT, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF ACH-0144471 TREATMENT FOR 6 MONTHS IN PATIENTS WITH C3 GLOMERULOPATHY (C3G) (P&S Industry Clinical Trial)

Mar 6 2018 - Mar 6 2023

C3 GLOMERULOPATHY BIOMARKER STUDY (P&S Industry Clinical Trial)

Mar 7 2017 - Mar 7 2022

A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATACICEPT IN IGA NEPHROPATHY (P&S Industry Clinical Trial)

Feb 23 2017 - Feb 23 2022

A NATURAL HISTORY STUDY TO OBSERVE DISEASE PROGRESSION, STANDARD OF CARE AND INVESTIGATE BIOMARKERS IN ALPORT SYNDROME PATIENTS (P&S Industry Clinical Trial)

Jan 12 2015 - Jan 12 2020

AN OPEN LABEL RANDOMIZED PHASE IV STUDY OF THE SAFETY AND EFFICACY OF ACTHAR GEL IN PATIENTS WITH MEMBROUS (CLASS V) LUPUS NEPHRITIS (P&S Industry Clinical Trial)

Dec 9 2014 - Dec 9 2019

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BMS-188667 (ABATACEPT) OR PLACEBO ON A BACKGROUND OF MYCOPHENOLATE MOFETIL (MMF) AND CORTICOSTEROIDS IN SUBJECTS WITH ACTIVE (P&S Industry Clinical Trial)

Jun 19 2014 - Jun 19 2019

ADVANCING CLINICAL RESEARCH IN PRIMARY GLOMERULAR DISEASES (UM1) (Federal Gov)

Sep 16 2013 - May 31 2018

BEACON 402-C-0903 (P&S Industry Clinical Trial)

Jan 10 2012 - Jan 10 2017

AAAF2403-ALEXION DDD (P&S Industry Clinical Trial)

Sep 2 2010 - Sep 2 2015

A PHASE IIA,MULTICENTER,RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVAULATE THE SAFETY, TOLERABILITY (P&S Industry Clinical Trial)

Jun 22 2010 - Jun 22 2015

THE TREATMENT OF RESISTANT NEPHROTIC SYNDROME WITH ACTH GEL (ACTHAR) (P&S Industry Clinical Trial)

Jan 4 2010 - Jan 4 2015

BELONG (P&S Industry Clinical Trial)

Nov 13 2008 - May 31 2014

LUPUS NEPHRITIS BIOMARKER STUDY: BASELINE CHARACTERISTICS OF PATIENTS (Private)

Jan 1 2011 - Dec 31 2013

THE NEPHROTIC SYNDROME STUDY NETWORK (Federal Gov)

Apr 1 2011 - Jun 30 2013

EVALUATE THE EFFICACY AND SAFETY OF RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OF IV LUPUS NEPHRITIS (P&S Industry Clinical Trial)

Mar 23 2006 - Jun 30 2012

ASSESS THE EFFICACY AND SAFETY OF MYCOPHENOLATE MOFETIL (MMFIN MAINTAINING REMISSION AND MAINTAINING REMISSION AND RENAL (P&S Industry Clinical Trial)

Nov 11 2005 - May 31 2010

THE FOCAL SEGMENTAL GLOMERULOSCLEROSIS CLINICAL TRIAL (Federal Gov)

Sep 1 2005 - Aug 31 2008

Selected Publications

282) Herlitz L, Bomback AS, Markowitz GS, Stokes MB, Smith RN, Colvin RB, Appel GB, D’Agati VD. Pathology after eculizumab Treatment for Dense Deposit Disease and C3 Glomrulonephritis. JASN 23:1229-1237,2012. 283) Bomback AS, Smith RJ, Barile GR, Zhang Y, Heher EC, Herlitz L, Stokes MB, Markowitz GS, D’Agati V, Canetta PA, Radhakrishnan J, Appel GB. Eculizumab for the Treatment of Dense Deposit Disease and C3 Glomrulnephritis. CJASN 7:748-756 2012. 284) Appel AS, Appel GB. Treatment of Lupus Nephritis. Renal & Urology News 2012. 285) Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J ,Appel GB. Aldosterone breakthough during aliskiren, valsartan, and combination ( aliskiren + valsartan) therapy. Journal of Amer Soc Hypertension. 6:338-345, 2012. 286) Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nature Review Nephrology 8:634-642, 2012. 287) Sprangers B, Monahan M, Appel GB. Diagnosis and Teatment of Flares of Lupus Nephritis – An Update. Nature Reviews. Nephrology 8: 709-717, 2012 288) Morris H, Canetta PA, Appel GB. Impact of the ALMS and Maintain trials on the Management of Lupus Nephritis. Neph Dial Transplant 28 : 1371-1376, 2013. 289) Appel GB. Rituximab in Membranous Nephropathy: Is it a first-line treatment. JASN 23:1280-82, 2012. 290) Anders H-J, Appel GB. Implications of the Novel ACR Guidelines in the Management of Lupus Nephtiris. Nature Rev Neph. 8:500-509, 2012. 291) Appel GB, Appel AS. New Diagnostic Tests and New Therapies for Glomerular Disease. Blood Purification 35:81-85, 2013. 292) Hogan J, Appel GB. Update on the Treatment of Lupus Nephritis – Current Opinion in Nephrology and Hypertension. 22:224-230,2013. 293) Gadegbeku CA, Gipson D, LozmanL, … Appel GB … Kretzler M. A Design of the Nephrotic Syndrome Study N etwork ( NEPTUNE )to evaluate primary glomerular nnephropathy by a multidisciplinary approach. Kidney Int. 1-8, 2013. 294) Appel GB. Chapter 47, pp 271-274 Parenchymal Renal Disease. in The Cleveland Clinic Foundation Intensive Review of Internal Medicine. Editors James K. Stoller, Craig Nielsen, Janet Buccola, and Andrei Brateane 6th edition, . Wolters Kluwer 2014. 295) Appel GB. Detecting and Controlling diabetic nephropathy: What do we know? Cleveland Clinic Journal of Medicine 80:209- 217. 2013. 296) Reiser J, Trachtman H, and Appel GB. Mechanisms of Proteinuria. Submitted for publication. 297) Appel GB. Membranoproliferative Glomerulonephritis.Mechnaisms and Treatment. Volume 181 pages 1-12, In press Contibutions in Nephrology edited by Prof Nan Chen. Basel, Karger 2013. 298) Appel GB, Rovin B, Jayne D. Lupus Nephritis in Comprehensive Clinical Nephrology ed by Johnson R, Floege J, Feehaly J, - Saunders - Elsevier, 2013. 299) Pickering M, D’Agati V, Nester C, …Appel GB, …H.T.Cook Consensus Report on C3 Glomerulonephritis. Submitted for Publication . 300) Appel GB, D’Agati VD. Focal Segemntal gomerulusclerosis in Comprehensive Clinical Nephrology ed by Johnson R, Floege J, Feehaly J, - Saunders - Elsevier, 2013. 301) Canetta PA, Kiryluk K, Appel GB. Emerging Tests and Therpies for IgA Nephropathy. Accepted for publiction CJASN “Moving Points”. 302) Hou JH, Markowitz GS, Bomback AS, Appel GB, Herlitz LC, Stokes MB, D’Agati VD. Toward a working definition of C3 Glomerulopathy by immunofluorescence. Accepted for publication Kidney Int. 303) Hogan J, Restivo M, Canetta P, Radhakrishnan J, Appel GB, Bomback AS.Rituximab Treatment for Fibrillary glomerulonephritis. Nephrology Dialysis and Transplantation in presss 304) Cohen SD, AppelG . Approach to the Patient with Chronic Glomerular Disease. IChapter 37: pages 441-452 Chronic Renal Disease edited by Paul Kimmel. And Mark Rosenberg Elsevier Press 2014 305) Bomback AS, Appel GB. ANCA-associated GN—to PLEX or not to PLEX? - Nature Reviews Nephrology 9:436-438, 2013. 306) Hogan J, BombackAS, Mehta K, Canetta PA, Rao MK, Appel GB, Radhakrishnan J, Lafayette RA . Treatment of Idiopathic Focal Segmental Glomerulosclerosis with Adrenocorticotropic Hormone Gel. Cl in J Am Soc Nephrol . Dec 2013 8( 12):207, 2013 307) Beyond therapy – Predictors of Treatment Response in a Randomized Trial for FSGS Susan L. Hogan1, Sharon Bartosh2, Bo Hu3, Howard Trachtman4, Larry Greenbaum5, Cheryl L. Tran, MD15 , Marva Moxey-Mims7, Gerald Appel8, Lorraine E. Bell9, Daniel Cattran10, Chandran Chandra11, Ana Paredes12, Dechu Puliyanda13, Mouin Seikaly14, Joshua Kaplan6, Dilys Whyte16, Vivette D’Agati8, Frederick Kaskel17, Milena Radeva3, Jennifer Gassman3, Tom Greene18, Debbie S. Gipson, MD19, Aaron Friedman20 ( submitted for publication) 308) Patel K, Bomback AS, Appel GB, Leung N, Dillon JJ, D’Agati VD, Canetta PA. Succesful use of Bortezomib in Heavy Chain Depostion Disease: a report of three cases. AJKD in press. 309) Avasare RS, Appel GB, Bombback AS. Aldosterone blockade as an alternative renin-angiotensin-aldosterone system blocking agent in cases of tretmetn associated anemis. Clin Nephrol 81:350-355,2014. 310) Hogan J, Mohan P, AppelGB. New Diagnostic and Therapeutics in Glomerular Disease . Amer J Kidney Disease in press. 311 ) Papeta N, Kiryluk K, Patel A, Steerken R, Kacak N, Snyder H, Imus P, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J, Wyatt CM, Ross MJ, Winston JA, Klotman ME, Cohen DJ, Appel GB, D’Agati VD, Klotman PE, Gharavi AG. APOL1 Variant Increase Risk for FSGS and HIVAN but Not IgA Nephropathy. JASN Nov 1,2011 22: 1991-1996, 2011